Invivo Therapeutics Holdings Corp  

(Public, OTCMKTS:NVIV)   Watch this stock  
Find more results for OTC:NVIV
0.620
+0.005 (0.73%)
Aug 29 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.60 - 0.65
52 week 0.58 - 2.67
Open 0.62
Vol / Avg. 297,547.00/283,477.00
Mkt cap 57.93M
P/E     -
Div/yield     -
EPS -0.25
Shares 93.43M
Beta 16.23
Inst. own 11%
Sep 10, 2014
Invivo Therapeutics Holdings Corp at Rodman & Renshaw Global Investment Conference - 9:10AM EDT - Add to calendar
Aug 6, 2014
Q2 2014 Invivo Therapeutics Holdings Corp Earnings Release
  

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -79.66% -233.76%
Return on average equity -126.74% -732.67%
Employees 45 -
CDP Score - -

Address

Suite B14402, One Kendall Square
CAMBRIDGE, MA 02139
United States - Map
+1-617-8635500 (Phone)

Website links

Description

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc. is a development-stage company. The Company is developing and commercializing technologies for the treatment of spinal cord injuries. The Company develops biopolymer scaffolding devices for the treatment of spinal cord injuries. The biopolymer devices are designed to protect the damaged spinal cord from further secondary injury and promote neuroplasticity, a process where functional recovery can occur through the rerouting of signalling pathways to the spared healthy tissue. The Company�s biopolymer-based devices are surgically implanted or injected into the lesion created during traumatic injury, or the primary injury. The Company�s porous biopolymer scaffold consists of polylactic-co-glycolic acid (PLGA) and-polylysine. The Company focuses to develop an injectable hydrogel designed to counteract the inflammatory environment.

Officers and directors

Mark D. Perrin Chief Executive Officer, Director
Age: 57
Steven F. McAllister Chief Financial Officer
Age: 56
Tamara L. Joseph J.D. Senior Vice President, Chief Compliance Officer, General Counsel
Age: 51
Thomas R. Ulich M.D. Chief Scientific Officer
Age: 60
John A. McCarthy Jr. Non-Executive Independent Chairman of the Board
Age: 54
Kenneth A. Di Pietro Independent Director
Age: 55
Richard J. Roberts Ph.D. Independent Director
Age: 70